Epizyme Inc (NASDAQ:EPZM) has been given a $20.00 price objective by research analysts at Royal Bank Of Canada in a note issued to investors on Saturday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target would suggest a potential upside of 41.34% from the company’s previous close.

Several other analysts also recently commented on EPZM. BidaskClub downgraded Epizyme from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Cowen and Company reissued a “buy” rating on shares of Epizyme in a research note on Wednesday, June 7th. Oppenheimer Holdings, Inc. began coverage on Epizyme in a research note on Thursday, April 13th. They issued an “outperform” rating and a $26.00 price objective for the company. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Tuesday, July 18th. Finally, Wedbush reissued an “outperform” rating and issued a $24.00 price objective on shares of Epizyme in a research note on Thursday, May 18th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $23.75.

Epizyme (NASDAQ EPZM) traded up 13.65% on Friday, reaching $14.15. The company’s stock had a trading volume of 696,451 shares. The company’s market cap is $825.77 million. The firm’s 50-day moving average price is $13.86 and its 200 day moving average price is $14.31. Epizyme has a 52-week low of $7.02 and a 52-week high of $18.50.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.08. The company had revenue of $10 million during the quarter, compared to analysts’ expectations of $3.95 million. The business’s revenue for the quarter was up 2027.7% compared to the same quarter last year. During the same period last year, the company earned ($0.49) earnings per share. Equities analysts anticipate that Epizyme will post ($2.42) EPS for the current fiscal year.

WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/06/royal-bank-of-canada-analysts-give-epizyme-inc-epzm-a-20-00-price-target.html.

In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $13.44, for a total transaction of $201,600.00. Following the completion of the sale, the insider now directly owns 22,228 shares of the company’s stock, valued at $298,744.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew E. Singer sold 3,024 shares of the stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $15.50, for a total value of $46,872.00. Following the sale, the chief financial officer now directly owns 40,529 shares of the company’s stock, valued at $628,199.50. The disclosure for this sale can be found here. Insiders have sold 50,524 shares of company stock valued at $746,797 over the last ninety days. 25.20% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of the stock. Legal & General Group Plc increased its stake in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. acquired a new stake in shares of Epizyme during the first quarter worth approximately $175,000. BB&T Securities LLC acquired a new stake in shares of Epizyme during the second quarter worth approximately $181,000. Trexquant Investment LP acquired a new stake in shares of Epizyme during the second quarter worth approximately $184,000. Finally, SG Americas Securities LLC increased its stake in shares of Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 6,072 shares during the last quarter. 81.63% of the stock is owned by institutional investors.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc and related companies with MarketBeat.com's FREE daily email newsletter.